Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions

被引:16
作者
Aronson, JK [1 ]
机构
[1] Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England
关键词
anecdotes; evidence; narrative;
D O I
10.1111/j.1365-2753.2005.00527.x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Anecdotal case reports contribute about one-third of the published literature on adverse drug reactions and interactions, but are regarded as providing poor-quality evidence. However, they can occasionally provide proof of cause and effect, and there are many other reasons for publishing them. Because an anecdote is a narrative, narratological paradigms from literature, art, and music can show how we can make evidential use of anecdotes. Useful paradigms are the dramatic unities (of time, place, and action), comprehensive catalogues, and pattern formations. Here I give examples of each of these types of paradigm and show how they can be used to interpret anecdotes about adverse drug reactions and interactions. The dramatic unities show how a proper classification of adverse drug reactions can be achieved, according to dose-relation, time-course, and susceptibility factors; use of this classification should improve the evidential use of anecdotal reports. A high background incidence of the effect (the medical equivalent of subplots, which violate the unity of action) makes it more difficult to detect adverse drug effects using anecdotal reports. To make best evidential use of the corpus of anecdotal reports of adverse drug reactions, comprehensiveness is important: each suspected adverse reaction should be reported in detail and reactions should be reported in sufficient numbers for proper classification and for patterns to be recognized. One form of pattern recognition, teleoanalysis of data, should, when possible, include not only randomized controlled trials and observational studies, but also case series and anecdotal reports.
引用
收藏
页码:195 / 208
页数:14
相关论文
共 37 条
[1]  
ABBOTT H. PORTER, 2002, CAMBRIDGE INTRO NARR, P12
[2]  
Aronson J., 2002, BMJ: British Medical Journal, V324, P1022
[3]   Joining the DoTS: new approach to classifying adverse drug reactions [J].
Aronson, JK ;
Ferner, RE .
BRITISH MEDICAL JOURNAL, 2003, 327 (7425) :1222-1225
[4]   ALTERED DISTRIBUTION OF DIGOXIN IN RENAL-FAILURE - CAUSE OF DIGOXIN TOXICITY [J].
ARONSON, JK ;
GRAHAMESMITH, DG .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1976, 3 (06) :1045-1051
[5]   Anecdotes as evidence - We need guidelinesfor reporting anecdotes of suspected adverse drug reactions [J].
Aronson, JK .
BRITISH MEDICAL JOURNAL, 2003, 326 (7403) :1346-1346
[6]   Adverse drug reactions: keeping up to date [J].
Aronson, JK ;
Derry, S ;
Loke, YK .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2002, 16 (01) :49-56
[7]  
ARONSON JK, 2005, IN PRESS DRUG SAFETY
[8]  
ARONSON JK, 2003, ELECT BRIT MED J
[9]   PROLONGED HALF-LIFE OF VERAPAMIL IN A CASE OF OVERDOSE - IMPLICATIONS FOR THERAPY [J].
BUCKLEY, CD ;
ARONSON, JK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (06) :680-683
[10]   Randomized, controlled trials, observational studies, and the hierarchy of research designs. [J].
Concato, J ;
Shah, N ;
Horwitz, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1887-1892